

### **18<sup>тн</sup> - 19<sup>тн</sup> DECEMBER 2021** SATURDAY & SUNDAY Time: 18:30 - 21:30

ORGANIZING SECRETARY



#### **Dr. Sushant Mittal** Consultant Medical Oncologist, Action Cancer Hospital, Delhi

Click the link below to register https://www.riverroute.in/sparssh-esmo2021



### 18<sup>TH</sup> - 19<sup>TH</sup> DECEMBER 2021 | 18:30 - 21:30

#### WELCOME ADDRESS

Dear Colleagues,

On behalf of Sparsh we invite you for an enlightening update titled "Whats new from ESMO 2021" to be held on Saturday 18<sup>th</sup> & Sunday 19<sup>th</sup> December 2021 on virtual Platform.

The ESMO Congress has always offered the stage for promising developments to be presented to the oncology community, looking beyond for the development of new agents, both for biomarker-driven and agnostic approach, but also to improve the management of resistance after molecular or immune treatments. Discussing the learnings of these prospects from an Indian context will help us in our the quest to significantly improve the survival and quality of life of our patients.

As personalised medicine has come of age, an ever-increasing number of genetic alterations in cancer cells are being identified as potential targets for novel therapies. Thanks to the increasingly widespread use of broad genetic testing and next-generation sequencing, drugs we know in oncology are now finding new potential applications: including the rare group which has no approved treatment options to date. Delivering anticancer agents straight to the core of the tumour cell with ADCs, and expanded horizons in immunotherapy with new combinations are some of the newer concepts presented at esmo which is important for us to discuss.

We have shortlisted some noteworthy data from ESMO to be discussed at this meeting which will cover all the major tumor types. Leading national faculty will throw light on the use of this new information in day to day practice. We expect around 300 delegates to be present at this meeting.

For our industry participation we have planned various scientific engagement and branding opportunities towards sponsorship.

We look forward to your participation in making this into a meaningful program.

Regards

**Dr. Sushant Mittal** Consultant Medical Oncologist, Action Cancer Hospital, Delhi **Dr. Samit Purohit** Consultant Medical Oncologist, Action Cancer Hospital, Delhi

Click the link below to register https://www.riverroute.in/sparssh-esmo2021




### 18<sup>TH</sup> DECEMBER 2021 | 18:30 - 21:30

WHATS NEW FROM

### SCIENTIFIC PROGRAM | DAY 1

	Session 1 : Breast Cancer
	Supported by Novartis
18:30 - 18:45	Consistently Superior OS in HR+HER2- aBC Speaker: Dr. Peush Bajpai
18:45 - 19:00	PIKing the right strategy in Management of HR+HER- aBC Speaker: Dr. Mohit Agarwal
Y O X	Supported by Lilly
19:00 - 19:40	Cancer does not take a day off then why should a CDK 4/6 inhibitor?
20 Mins	<ul> <li>Clinical Case presentation – Why I chose Abemaciclib for my HR+/HER2- MBC patient with Poor Prognostic Factors Moderator : Dr. Adwait Gore</li> </ul>
O X Y Y O X X Y O O X Y	<ul> <li>Q&amp;A - "Tailoring treatment in HR+ HER2- MBC based on the prognostic factors" Experts : Dr. Randeep Singh   Dr. Shirish Alurkar Dr. Bharat Vaswani   Dr. Ravi Wategaonkar</li> </ul>
20 Mins	<ul> <li>Clinical Case presentation – Why I chose Abemaciclib for my HR+/HER2- MBC patient with Poor Prognostic Factors Moderator : Dr. Bharat Vaswani</li> </ul>
X O X X Y O	Q&A - "Tailoring treatment in HR+ HER2- MBC based on the prognostic factors" Experts : Dr. Randeep Singh   Dr. Shirish Alurkar



Click the link below to register https://www.riverroute.in/sparssh-esmo2021




### 18<sup>TH</sup> DECEMBER 2021 | 18:30 - 21:30

WHATS NEW FROM

### SCIENTIFIC PROGRAM | DAY 1

-		-			
SIII	nn	ortc		$\mathbf{V}$ Dt	1701
Ju			FM N	y Pf	1251

19:55 - 20:15	Navigating Management with CDK 4/6 inhibitors : From Clinical Trials to Clinical Practice Speaker : Dr. Devavrat Arya
	Session 2 : Renal Cell Carcinoma (RCC)
	Supported by Industry Symposium
20:15 - 20.30	5-year follow-up : CheckMate 214 Speaker: Dr. Samit Purohit
	Session 3 : Hepatocellular Carcinoma (HCC)
•	Supported by Roche
20:30 - 20:50	Immunotherapy combination in management of Unresectable Hepatocellular carcinoma Speaker: Dr. Vineet Talwar
	Session 4 : Lung Cancer
	Supported by AstraZeneca
20:50 - 21:00	Experience sharing on Durvalumab in ES-SCLC Speaker : Brig. Rajeshwar Singh
21:00 - 21:10	Newer paradigm in the treatment of Resected EGFRm NSCLC Speaker : Dr. Ullas Batra
21:10 - 21:20	Management of 1st line Ca Ovary - Bringing Precision to Medicine" Speaker : Dr. Manish Singhal
21:20 - 21:30	• Q & A With discussion



Click the link below to register https://www.riverroute.in/sparssh-esmo2021



### 19<sup>TH</sup> DECEMBER 2021 | 18:30 - 21:30

### SCIENTIFIC PROGRAM | DAY 2

	Session 5 : Prostate Cancer
	Supported by Lupin
18:30 - 18:45	CHECKMATE 9 KD - rucaparib + nivoloumab in Prostate Cancer Speaker: Dr. Kumar Deep
	Session 6 : Gastric Cancer
	Supported by Lilly
18:45 - 19:05	Clinical case based discussion of an <b>advanced</b> Gastric Cancer patient Moderator: Dr. Prasad Narayanan Experts: Dr. Anita Ramesh   Dr. Rahul Sud
	Session 7 : Lung Cancer
19:05 - 19:25	Clinical case based discussion: Does one size fit all? What information will help improve our treatment decisions in EGFRm+ advanced NSCLC? Moderator: Dr. Ghanashyam Biswas Experts: Dr. Chandrakanth M.V.   Dr. S.S. Nirni
	Supported by Novartis
19:25 - 19:40	CAPMATINIB: unlocking the unmet need in MET ex14 skipping NSCLC Speaker: Dr. Manish Singhal
19:40 - 19:55	Personalized therapy to further improve outcomes in patients with BRAF mutated mNSCLC Speaker: Dr. Chandragouda

19:55 - 20:15		۲Fi	Supported by Pfizer First line treatment of ALK rearranged NSCLC Speaker: Dr. Rajat Bajaj										
20:15 - 20:35			m	Exon 19 deletion and exon 21 L858R substitution mutation: Are they same? Speaker: Dr. Chaturbhuj Agrawal									

Click the link below to register https://www.riverroute.in/sparssh-esmo2021



### 19<sup>TH</sup> DECEMBER 2021 | 18:30 - 21:30

### SCIENTIFIC PROGRAM | DAY 2

	Supported by Roche				
20:35 - 20:55	Atezolizumab in 1st line mNSCLC (IMPOWER 110/130/150) Speaker: Dr. Shyam Aggarwal				
•	Supported by ESAI				
21:55 - 21:05	2nd line treatment options in advance RCC Speaker: Dr. Sushant Mittal				
21:05 - 21:30	Concluding Remarks				



Click the link below to register https://www.riverroute.in/sparssh-esmo2021



### 18<sup>TH</sup> - 19<sup>TH</sup> DECEMBER 2021 | 18:30 - 21:30

### VIRTUAL EVENT MANAGED BY

### rivezoute<sup>®</sup>

Leaders in Streaming Modules

### Sarika Barne

Webinar Manager, River Route Event, Mumbai Mobile: +91 99301 94266 | E-mail : rrcgsarika@gmail.com

Click the link below to register

https://www.riverroute.in/sparssh-esmo2021